Ken Griffin
TRIB

Ken Griffin’s Trinity Biotech TRIB Stock Holding History

Ken Griffin’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-373
Closed -$8.86K – 14243
2025
Q4 		$8.86K Buy
+373
New +$11K ﹤0.01% 12437
2024
Q3 		– Sell
-1
Closed -$41 – 15270
2024
Q2 		$41 Buy
+1
New +$58 ﹤0.01% 14116
2023
Q3 		– Sell
-1
Closed -$97 – 15122
2023
Q2 		$97 Hold
1
– – ﹤0.01% 14223
2023
Q1 		$94 Buy
+1
New +$155 ﹤0.01% 14592
2021
Q3 		– Sell
-149
Closed -$66K – 14666
2021
Q2 		$66K Sell
149
-82
-35% -$40.9K ﹤0.01% 13204
2021
Q1 		$130K Buy
+231
New +$167K ﹤0.01% 12204

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ken Griffin's TRIB Position: Q4 2025 in Review

Ken Griffin sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 1,313 shares — an estimated $38.7K sold.

Ken Griffin first reported a position in TRIB in Q4 2013 and held it in 21 quarters. The position peaked at $892K in Q1 2015. 25 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • Ken Griffin reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 1,313 Trinity Biotech shares in Q4 2025, an estimated $38.7K.
  • Ken Griffin first reported a position in Trinity Biotech in Q4 2013 and held it in 21 quarters.
  • Ken Griffin's Trinity Biotech position peaked at $892K in Q1 2015.
  • 25 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.